Cargando…
Plasma and tissue disposition of mitozolomide in mice.
When mitozolomide was administered i.p. to mice, drug disposition appeared to fit a simple, one-compartment kinetic model with an elimination half-life of less than 1 h. The disposition of mitozolomide in mice bearing the ROS osteosarcoma, also followed a first-order process but in this case the eli...
Autores principales: | Brindley, C. J., Antoniw, P., Newlands, E. S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001482/ https://www.ncbi.nlm.nih.gov/pubmed/3456242 |
Ejemplares similares
-
Phase II evaluation of mitozolomide in ovarian cancer.
por: Harding, M., et al.
Publicado: (1988) -
Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.
por: Goddard, C., et al.
Publicado: (1985) -
Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986) -
Mitozolomide-induced sensitisation of mammalian cells in vitro to radiation.
por: McKeage, M. J., et al.
Publicado: (1989) -
The effects of pretreatment of human tumour cells with MNNG on the DNA crosslinking and cytotoxicity of mitozolomide.
por: Gibson, N. W., et al.
Publicado: (1985)